When compared to the E. coli-produced Nc-aD VLPs and the commercial hepatitis B vaccine, Engerix B, the antibody titre elicited by the Sf9-produced Nc-aD VLPs was significantly higher at all points studied. This evidence concerns the gene CDH2 and hepatitis B virus infection.